Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaOfatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataChronic lymphocytic leukemia: a clinical review including Korean cohortsNew developments in the management of chronic lymphocytic leukemia: role of ofatumumabClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaIbrutinib (PCI-32765) in chronic lymphocytic leukemiaNew antibody approaches to lymphoma therapyNovel CD20 monoclonal antibodies for lymphoma therapyInduced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomesManagement of chronic lymphocytic leukemia.Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patientsAdvances in treating chronic lymphocytic leukemiaTransplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Choosing first-line therapy for chronic lymphocytic leukemia.Therapeutic antibodies against cancer.Initial treatment of CLL: integrating biology and functional status.Therapeutic advancement of chronic lymphocytic leukemia.Chronic lymphocytic leukemia: inception to cure: are we there?Ibrutinib: a paradigm shift in management of CLL.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).What do we do with chronic lymphocytic leukemia with 17p deletion?Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.The role of monoclonal antibodies in the treatment of lymphomas.The current status and future impact of targeted therapies in non-Hodgkin lymphoma.Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.New treatment options for chronic lymphocytic leukemia.Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
P2860
Q24203027-CAA64A6A-6D05-4DC6-843B-315A206D2ED3Q26738934-C09FD881-3B9D-484E-9E67-F2F3D0B1C1D3Q26752467-3960A272-525E-4C91-8018-95EFC53BE93DQ26768396-139DA6B2-C9AC-45B6-BC7B-DD291CB12A92Q26783600-3E15C028-1CF9-479A-AB47-DED9CEB5111FQ26852328-C9150285-6BEA-426C-823B-0EB26A430B25Q27022373-EA785F48-8E34-444D-8696-2BF02C710849Q28390112-703A0CCB-E1EA-46F1-83F9-2DE7FE3BCA31Q30405847-FAE9A100-39D4-4C1A-9A6E-666FE100FD26Q33406478-537EFB3E-330F-4A3A-850B-036C8EBBE1B8Q33419843-0F861872-49A7-48FC-88FC-0292A04E2192Q33441123-C16C89B2-4ABD-4EA3-9AE0-E8DFAFFD774DQ33558148-95078E94-9C70-484F-847E-64D6FF04E593Q33695912-95ADBDB5-798C-41A4-9516-EB41A45F4FD1Q33903379-CCC242FD-6729-4B6D-A52F-73D41EB8D39DQ34019917-603C79F0-042B-4F9B-B08C-DCCEFDCB90BEQ34625543-EE86E944-A1ED-43E0-8C69-101C458575F8Q35124844-77357D5F-2DCC-4960-B514-B17CE2319032Q35908498-54DF01DA-114A-4DBE-9CC2-8447F0171581Q36219647-022D7B92-9303-4D59-800D-77D6CC43E97CQ36300303-EDD14EB4-58C8-4224-8394-A8978863025BQ36609259-B94DE1F5-2B92-4B65-B751-52F659062E48Q36739295-DA4EFC49-40D2-4CDB-B71E-722128FDE875Q37178611-F2B563DC-CDC2-4737-8879-4DABEE0C1403Q37487919-2D865CA5-007F-41EB-BA88-28CB391E2B48Q37975154-E0123DC4-C21A-469F-BB6B-AC1EC6F7A9A7Q37980900-636AF87A-0353-4495-AA21-6F6E0BF35187Q38029382-8F4224CF-3E5A-4E73-9665-E607548E432EQ38061883-58EC63E9-282C-4AC9-89E6-B12FBBDEF345Q38063170-DC98305A-F71A-44CA-84E3-5CF25305FFBEQ38068494-85A96370-B3F8-41D4-BAD6-B7ED5AC07F6BQ38068932-8CE080D7-2A9A-49E2-A170-707368F77B4DQ38069595-3F469445-2499-4683-8758-DE78D3002019Q38095123-55748777-7D13-42CC-93A9-9D22FF186114Q38100787-6AACAAD0-1472-4B37-8D14-633ECA755910Q38126946-507EC9F8-9900-4843-B271-D4B1C135CD14Q38155343-0DAF1F96-111B-4EBB-A792-77F03115989EQ38190095-ECFB7D65-3EE1-4153-A0A5-2F1F57FC2C1EQ38221686-198BD12A-D0B6-4ADC-86AE-2FA3FD06BA3CQ38231432-8841ABCA-084D-47E8-A7EC-4D66435AC561
P2860
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.
@ast
Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.
@en
type
label
Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.
@ast
Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.
@en
prefLabel
Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.
@ast
Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P50
P1433
P1476
Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.
@en
P2093
407 Study Investigators
Chai-Ni Chang
Charlotte A Russell
Francisco J Hernandez-Ilizaliturri
Geoffrey Chan
Georg Hess
Jirí Mayer
Laimonas Griskevicius
P2860
P304
P356
10.1182/BLOOD-2010-12-323980
P407
P577
2011-04-15T00:00:00Z